CN111132984A - 凋亡信号调节激酶1抑制剂的盐及其晶型 - Google Patents

凋亡信号调节激酶1抑制剂的盐及其晶型 Download PDF

Info

Publication number
CN111132984A
CN111132984A CN201980004581.7A CN201980004581A CN111132984A CN 111132984 A CN111132984 A CN 111132984A CN 201980004581 A CN201980004581 A CN 201980004581A CN 111132984 A CN111132984 A CN 111132984A
Authority
CN
China
Prior art keywords
acid
compound
iii
ray powder
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980004581.7A
Other languages
English (en)
Inventor
李宗斌
匡远卓
呙临松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Publication of CN111132984A publication Critical patent/CN111132984A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

凋亡信号调节激酶1抑制剂的盐及其晶型。具体涉及一种具有通式(I)化合物的酸加成盐及其晶型、制备方法和应用以及含有治疗有效量的该盐的药物组合物。

Description

PCT国内申请，说明书已公开。

Claims (35)

  1. PCT国内申请，权利要求书已公开。
CN201980004581.7A 2018-08-14 2019-08-14 凋亡信号调节激酶1抑制剂的盐及其晶型 Pending CN111132984A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810924943 2018-08-14
CN2018109249431 2018-08-14
PCT/CN2019/100556 WO2020034988A1 (zh) 2018-08-14 2019-08-14 凋亡信号调节激酶1抑制剂的盐及其晶型

Publications (1)

Publication Number Publication Date
CN111132984A true CN111132984A (zh) 2020-05-08

Family

ID=69525119

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980004581.7A Pending CN111132984A (zh) 2018-08-14 2019-08-14 凋亡信号调节激酶1抑制剂的盐及其晶型

Country Status (3)

Country Link
CN (1) CN111132984A (zh)
TW (1) TW202021967A (zh)
WO (1) WO2020034988A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110577534B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577539B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577538B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577535B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577533B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577540B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577541B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577536B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577537B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108574A (zh) * 2014-12-23 2017-08-29 吉利德科学公司 Ask1抑制剂的固体形式
WO2018133865A1 (zh) * 2017-01-22 2018-07-26 福建广生堂药业股份有限公司 Ask1抑制剂及其制备方法和应用
WO2018133866A1 (zh) * 2017-01-22 2018-07-26 福建广生堂药业股份有限公司 作为ask1抑制剂的吡啶衍生物及其制备方法和应用
CN109400625A (zh) * 2017-08-17 2019-03-01 广东东阳光药业有限公司 稠合双环类化合物及其在药物中的应用
CN109983007A (zh) * 2017-03-03 2019-07-05 江苏豪森药业集团有限公司 酰胺类衍生物抑制剂及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2881742B1 (fr) * 2005-02-10 2007-09-07 Aventis Pharma Sa Pyrroles substitues, compositions les contenant, procede de fabrication et utilisation
TWI625121B (zh) * 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
CN110036005B (zh) * 2016-11-16 2022-09-27 广东东阳光药业有限公司 酰胺衍生物及其在药物中的应用
WO2018151830A1 (en) * 2017-02-17 2018-08-23 Fronthera U.S. Pharmaceuticals Llc Pyridinyl based apoptosis signal-regulation kinase inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108574A (zh) * 2014-12-23 2017-08-29 吉利德科学公司 Ask1抑制剂的固体形式
WO2018133865A1 (zh) * 2017-01-22 2018-07-26 福建广生堂药业股份有限公司 Ask1抑制剂及其制备方法和应用
WO2018133866A1 (zh) * 2017-01-22 2018-07-26 福建广生堂药业股份有限公司 作为ask1抑制剂的吡啶衍生物及其制备方法和应用
CN109983007A (zh) * 2017-03-03 2019-07-05 江苏豪森药业集团有限公司 酰胺类衍生物抑制剂及其制备方法和应用
CN109400625A (zh) * 2017-08-17 2019-03-01 广东东阳光药业有限公司 稠合双环类化合物及其在药物中的应用

Also Published As

Publication number Publication date
TW202021967A (zh) 2020-06-16
WO2020034988A1 (zh) 2020-02-20

Similar Documents

Publication Publication Date Title
CN111132984A (zh) 凋亡信号调节激酶1抑制剂的盐及其晶型
CN109983007B (zh) 酰胺类衍生物抑制剂及其制备方法和应用
JP6609065B2 (ja) １−（５−（２，４−ジフルオロフェニル）−１−（（３−フルオロフェニル）スルホニル）−４−メトキシ−１ｈ−ピロール−３−イル）−ｎ−メチルメタンアミンの新規な酸付加塩
JP6898043B2 (ja) ＴｒｋＡ阻害活性を有する含窒素複素環および炭素環誘導体
KR20080044841A (ko) 이마티닙 메실레이트의 다형 및 신규한 결정형과 비결정형및 α형의 제조 방법
BR112012012529B1 (pt) Composto indol, composição farmacêutica, inibidores e agentes compreendendo o referido composto e seus usos
TW202019913A (zh) 細胞壞死抑制劑及其製備方法和用途
CN112300153B (zh) 一种杂环化合物、药物组合物和用途
JP7100625B2 (ja) 置換２－ｈ－ピラゾール誘導体の結晶形、塩型及びその製造方法
US20090076272A1 (en) Polymorphs of eszopiclone malate
EA028146B1 (ru) Пролекарства аминохиназолинового ингибитора киназы
TW202208375A (zh) ４－胺基－５－（６－（４－甲基哌－１－基）－１ｈ－苯并［ｄ］咪唑－２－基）噻吩并［２，３－ｂ］吡啶－６（７ｈ）－酮之鹽及晶形
CN110577526B (zh) 溴域结构蛋白抑制剂的盐及其制备方法和应用
WO2016023330A1 (zh) 喹唑啉衍生物
KR101804749B1 (ko) 히스타민 ｈ3 수용체 길항제의 신규 푸마레이트 염
WO2021129841A1 (zh) 用作ret激酶抑制剂的化合物及其应用
WO2023083356A1 (zh) 固体形式的氮杂稠环酰胺类化合物及其用途
WO2021223748A1 (zh) 大环类酪氨酸激酶抑制剂的晶型及其制备方法
CN115536657A (zh) 一种联苯类衍生物抑制剂的盐、其晶型及其制备方法
CN114478586A (zh) 一种含二并环类衍生物抑制剂盐或晶型及其制备方法和应用
CA3198559A1 (en) Crystal form of free base of inhibitor containing bicyclic ring derivative and preparation method and application of crystal form
TW202102487A (zh) N-(5-((4-乙基哌𠯤-1-基)甲基)吡啶-2-基)-5-氟-4-(3-異丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺及其鹽的結晶與非晶型以及其製備方法與醫療用途
JP2014521729A (ja) ピラゾロピリミジノン化合物の塩、多形体およびその薬物組成物、製造方法および応用
JP2022517396A (ja) Ｅｇｆｒ阻害剤の塩、結晶形及びその製造方法
US11066401B2 (en) Pyrimidine compound, chloride salt thereof, and manufacturing and application of same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination